Lung cancer
Conditions
Interventions
Case series:Apatinib combined with gefitinib
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old, male or female; 2. Egfr-positive patients with stage II, III, and IV NSCLC, including: patients who can continue to use EGFR-TKIS after progression of first-line EGFR-TKIS treatment; 3. T790M mutation was negative and cMET amplification was negative; 4. Participate in the study voluntarily and sign the informed consent; 5. The researchers think there are benefits; 6. ECOG PS 0-2.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with contraindications associated with apatinib or EGFR-TKIS (e.g., active bleeding, ulcers, perforation of the intestine, intestinal obstruction, uncontrolled hypertension, grade III-IV cardiac insufficiency, 30 days after major surgery, and severe hepatic and renal insufficiency); 3. The doctor considers the patient who is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactWang Ke
West China Hospital, Sichuan University
Outcome results
None listed